Voxel S.A. - Asset Resilience Ratio
Voxel S.A. (VOX) has an Asset Resilience Ratio of 0.32% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read VOX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2023)
This chart shows how Voxel S.A.'s Asset Resilience Ratio has changed over time. See what is Voxel S.A.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Voxel S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Voxel S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł2.19 Million | 0.32% |
| Total Liquid Assets | zł2.19 Million | 0.32% |
Asset Resilience Insights
- Limited Liquidity: Voxel S.A. maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Voxel S.A. Industry Peers by Asset Resilience Ratio
Compare Voxel S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Check-Cap Ltd.
NASDAQ:MBAI |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Voxel S.A. (2018–2023)
The table below shows the annual Asset Resilience Ratio data for Voxel S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.18% | zł6.23 Million ≈ $1.71 Million |
zł529.03 Million ≈ $145.60 Million |
-0.10pp |
| 2022-12-31 | 1.28% | zł5.99 Million ≈ $1.65 Million |
zł467.35 Million ≈ $128.62 Million |
+1.16pp |
| 2021-12-31 | 0.12% | zł615.80K ≈ $169.48K |
zł495.05 Million ≈ $136.24 Million |
-0.39pp |
| 2020-12-31 | 0.51% | zł2.25 Million ≈ $620.42K |
zł438.23 Million ≈ $120.61 Million |
-4.25pp |
| 2019-12-31 | 4.76% | zł16.08 Million ≈ $4.43 Million |
zł337.91 Million ≈ $93.00 Million |
-0.28pp |
| 2018-12-31 | 5.04% | zł14.22 Million ≈ $3.91 Million |
zł282.33 Million ≈ $77.70 Million |
-- |
About Voxel S.A.
Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.